Clinical Trials | A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral CDK2 Degrader NKT3964 in Adults with Advanced/Metastatic Solid Tumors
A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral CDK2 Degrader NKT3964 in Adults with Advanced/Metastatic Solid Tumors
The University of Virginia seeks adults 18 years of age and older for a clinical trial. You may be eligible for this study if you have recurrent ovarian cancer, endometrial cancer, gastric or gastroesophageal cancer, small cell lung cancer, triple negative breast cancer, HR+ breast cancer, or other solid tumors with CCNE1 amplification. The goal of this clinical trial is to evaluate a medication called NKT3964 in treating your cancer. This study will include: maintaining a pill diary, electrocardiogram (ECG), echocardiogram (ECHO) or multigated acquisition scan (MUGA), blood draws, eye exams, tumor imaging assessments, and physical examinations. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. More information can be found here: https://clinicaltrials.gov/study/NCT06586957 Compensation: $65 per study visit In order to upload your website ad – Complete the below fields